Sugi Predict

Sugi Predict / Compounds / SCHEMBL1679690

SCHEMBL1679690

SCHEMBL1679690

CC(C)(C(=O)O)c1ccc(-c2ccccc2)cc1

nearest known ligand 0.61

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ CYP2C9 P11712 1/20 0.61
▸ MAPT P10636 3/20 0.57
▸ KMT2A Q03164 1/20 0.57
▸ SGK1 O00141 1/20 0.54
▸ SMN1; SMN2 Q16637 2/20 0.48
▸ APP P05067 1/20 0.47
▸ PTPN5 P54829 1/20 0.47
▸ MAP4K4 O95819 1/20 0.47
▸ KIF11 P52732 1/20 0.46
▸ NPC1 O15118 1/20 0.45
▸ RAB9A P51151 1/20 0.45
▸ CTDSP1 Q9GZU7 1/20 0.45
▸ RXRA P19793 1/20 0.44
▸ RXRB P28702 1/20 0.44
▸ HRH3 Q9Y5N1 1/20 0.44
▸ PTGS2 P35354 1/20 0.44
▸ L3MBTL1 Q9Y468 1/20 0.44

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6571 0.86 MAPT (0.67) CYP2C9MAPTKMT2A
SCHEMBL3497043 0.86 MAPT (0.52) CYP2C9MAPTKMT2ASGK1APP
SCHEMBL29033303 0.84 MAPT (0.64) MAPTKMT2A
SCHEMBL27888039 0.84 MAPT (0.64) CYP2C9MAPTKMT2A
SCHEMBL27514359 0.84 MAPT (0.64) CYP2C9MAPTKMT2A
Hydrochloric Acid SCHEMBL8899483 0.84 MAPT (0.64) MAPTKMT2A
Methyl Alcohol SCHEMBL5282426 0.84 MAPT (0.64) CYP2C9MAPTKMT2A
SCHEMBL3087883 0.83 CYP2C9 (0.61) CYP2C9MAPTKMT2ASMN1; SMN2PTPN5
Ethylene SCHEMBL28867982 0.82 MAPT (0.61) CYP2C9MAPTKMT2ASMN1; SMN2
SCHEMBL27904843 0.82 MAPT (0.61) CYP2C9MAPTKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2046119-A2 TREATMENT OF PSYCHIATRIC DISORDERS Myriad Genetics, Inc. (US) 2009-04-15 — — EP claimed
WO-2008006099-A2 TREATMENT OF PSYCHIATRIC DISORDERS MYRIAD GENETICS, INC. (US) 2008-01-10 — — WO claimed
US-11512071-B2 Decarboxylative cross-coupling and applications thereof THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2022-11-29 — — US disclosed
US-20200148668-A1 DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY 2020-05-14 — — US disclosed
US-10538509-B2 Decarboxylative cross-coupling and applications thereof THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2020-01-21 — — US disclosed
US-9611291-B2 Use of a tetraphenylborate (TPB) salt for the separation of biomolecules CORDEN PHARMA BRUSSELS PC (BE) 2017-04-04 — — US disclosed
EP-3126545-A2 DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF The Trustees of Princeton University (US) 2017-02-08 — — EP disclosed
US-20170022185-A1 DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY 2017-01-26 — — US disclosed
WO-2015153381-A2 DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF THE TRUSTEES OF PRINCETON UNIVERSITY (US) 2015-10-08 — — WO disclosed
US-20110098446-A1 Use of a tetraphenylborate (TPB) salt for the separation of biomolecules SOLVAY (SOCIETE ANONYME) (BE) 2011-04-28 — — US disclosed
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD MYRIAD GENETICS, INCORPORATED (US) 2009-06-18 — — US disclosed
WO-2008006099-A2 TREATMENT OF PSYCHIATRIC DISORDERS MYRIAD GENETICS, INC. (US) 2008-01-10 — — WO disclosed
CN-101022810-A Novel biaromatic compounds which activate peroxisome proliferator activated receptor-like receptors and their use in cosmetic or pharmaceutical compositions GALDERMA RES & DEV (FR) 2007-08-22 — — CN disclosed
EP-1201661-A1 HETEROAROMATIC RING COMPOUNDS SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) 2002-05-02 — — EP disclosed
US-6284768-B1 Src family SH2 domain inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2001-09-04 — — US disclosed
US-6268365-B1 Src family SH2 domain inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. 2001-07-31 — — US disclosed
EP-1045836-A1 PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2000-10-25 — — EP disclosed
US-6054470-A Src family SH2 domain inhibitors BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2000-04-25 — — US disclosed
WO-1999031066-A1 PYRIDONES AS SRC FAMILY SH2 DOMAIN INHIBITORS BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 1999-06-24 — — WO disclosed
EP-0065488-B1 PROCESS FOR THE PREPARATION OF 4-THIO-AZETIDINONE COMPOUNDS CIBA-GEIGY AG (CH) 1985-08-14 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170022185-A1 DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF PPOX, DDO, DDC CYP2C9 392/4885MAPT 2906/4885KMT2A 1610/4885
US-11512071-B2 Decarboxylative cross-coupling and applications thereof PPOX, DDO, DDC CYP2C9 392/4885MAPT 2906/4885KMT2A 1610/4885
US-10538509-B2 Decarboxylative cross-coupling and applications thereof PPOX, DDC, DDO CYP2C9 340/4885MAPT 3004/4885KMT2A 1237/4885
US-20090155903-A1 PHARMACEUTICAL COMPOSITION AND METHOD APP, PSEN2, PSEN1 CYP2C9 801/4885MAPT 6/4885KMT2A 2408/4885
US-20200148668-A1 DECARBOXYLATIVE CROSS-COUPLING AND APPLICATIONS THEREOF PPOX, DDO, DDC CYP2C9 392/4885MAPT 2906/4885KMT2A 1610/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.